종양학 바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Oncology Biomarker Market size is expected to reach USD 134.50 Billion in 2034 from USD 44.17 Billion (2025) growing at a CAGR of 13.17% during 2026-2034.

The global oncology biomarker market is expanding rapidly as cancer diagnosis and treatment increasingly rely on precision medicine. Oncology biomarkers help detect cancer at an early stage, predict treatment responses, and monitor disease progression. Rising cancer incidence worldwide and the need for more accurate diagnostic tools are driving the adoption of biomarker-based testing in clinical practice and research.

Advancements in molecular diagnostics, genomic sequencing, and proteomics technologies are major factors accelerating market growth. Biomarkers are widely used in targeted therapies and clinical trials to identify suitable patient populations and improve treatment outcomes. Pharmaceutical companies are also investing heavily in biomarker research to support the development of innovative cancer therapies and personalized treatment approaches.

Looking ahead, the oncology biomarker market is expected to witness strong growth due to continuous research and technological innovation. The increasing use of liquid biopsy, companion diagnostics, and AI-driven data analysis will further enhance biomarker discovery and application. As healthcare systems emphasize early cancer detection and personalized treatment strategies, the demand for oncology biomarkers will continue to rise globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Others

By Application

• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Others

By Technology

• Imaging Technology
• OMICS

COMPANIES PROFILED

• Abbott, Qiagen, Thermo Fisher Scientific Inc, Affymetrix Inc, Illumina Inc, Agilent Technologies, F HoffmannLa Roche AG, Merck Co Inc, Hologic Inc, Sino Biological Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLOGY BIOMARKER MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLOGY BIOMARKER MARKET: BY BIOMOLECULE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Biomolecule
• 5.2. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Epigenetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metabolic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Proteomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLOGY BIOMARKER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery and Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLOGY BIOMARKER MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Imaging Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. OMICS Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLOGY BIOMARKER MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Biomolecule
  • 8.2.3 By Application
  • 8.2.4 By Technology
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Biomolecule
  • 8.3.3 By Application
  • 8.3.4 By Technology
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Biomolecule
  • 8.4.3 By Application
  • 8.4.4 By Technology
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Biomolecule
  • 8.5.3 By Application
  • 8.5.4 By Technology
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Biomolecule
  • 8.6.3 By Application
  • 8.6.4 By Technology
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ONCOLOGY BIOMARKER INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott
  • 10.2.2 Qiagen
  • 10.2.3 Thermo Fisher Scientific Inc
  • 10.2.4 Affymetrix Inc
  • 10.2.5 Illumina Inc
  • 10.2.6 Agilent Technologies
  • 10.2.7 F. Hoffmann-La Roche AG
  • 10.2.8 Merck & Co. Inc
  • 10.2.9 Hologic Inc
  • 10.2.10 Sino Biological Inc